Disease/Condition
784 Clinical Trials
10+ Countries
Atopic Dermatitis Clinical Trials Database - Free Access to 784 Studies
Access comprehensive clinical trial information for Atopic Dermatitis through Pure Global AI's free database. This collection includes 784 clinical trials across multiple phases including N/A, Phase 2, Phase 3. Currently, 152 trials are actively recruiting participants.
Research for Atopic Dermatitis is being conducted in United States of America, China, Germany and 7+ other countries. Leading sponsors include LEO Pharma and Eli Lilly and Company. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Free Database
Powered by Pure Global AI
840K+ Global Trials
Updated Daily
By Phase
N/A
292Phase 2
189Phase 3
114Phase 1
73Phase 4
68By Status
Completed
400Recruiting
152Not yet recruit...
98Terminated
41Unknown
31Top Countries
United States of America176
China52
Germany32
Japan28
South Korea24
Top Sponsors
LEO Pharma37
Eli Lilly and Comp...26
AbbVie19
Pfizer17
Amgen16
Recent Trials
Latest clinical trials for Atopic Dermatitis
2018-000904-40
Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis
Pfizer Inc.
2015-001040-11
Proactive treatment with 0.03% tacrolimus cream in children with moderate/severe dermatitis
Astellas Pharma China, Inc.
2020-000875-20
Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis
Pfizer Inc.
2019-002836-10
A Study of Crisaborole ointment 2% in children aged 3-24 months with mild to moderate atopic dermatitis
Pfizer Inc.
2021-006538-38
A STUDY TO EVALUATE IF CRISABOROLE OINTMENT 2% WORKS WELL AND SAFE IN 2 YEARS AND OLDER CHINESE AND JAPANESE ECZEMA PATIENTS
Pfizer Inc.
2018-000731-27
Safety And Efficacy Of AN2728 Topical Ointment, 2% In Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis
Pfizer Inc.
2017-001765-25
An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Openlabel Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children
Novartis
NCT06421740
Not yet recr...
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
AbbVie
NCT06415175
Not yet recr...
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
Sanofi
NCT06412094
Completed
Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis
Avanta Trading Ltd.Russian Federation
NCT06397911
Phase 2
Not yet recr...
Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd.
NCT06397781
Phase 4
Not yet recr...
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Boston Children's Hospital
NCT06395948
Phase 2
Recruiting
A Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.Canada,United States of America
NCT06389136
Phase 3
Not yet recr...
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie
NCT06383468
Phase 3
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
AkesoChina
NCT06363461
Phase 2
Recruiting
Study of TDM-180935 in Atopic Dermatitis Patients
Technoderma Medicines Inc.United States of America
NCT06345404
Phase 1
Recruiting
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Corvus Pharmaceuticals, Inc.United States of America
NCT06311682
Phase 3
Not yet recr...
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
NCT06366932
Phase 4
Recruiting
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
Instituto de Investigación Hos...Spain
NCT06309355
Phase 2
Not yet recr...
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
Hangzhou Yirui Pharmaceutical ...United States of America
About Atopic Dermatitis Research
Pure Global AI provides free access to 784 clinical trials studying Atopic Dermatitis, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include LEO Pharma, Eli Lilly and Company, AbbVie, among others.
Quick Facts
Total Trials784
Countries10+
Sponsors10+
Recruiting152